Physician profile
Samar Bursheh
NPI 1154573665
$4,218.31
in general payments reported to CMS, 2019-2025
26 companies · $431 in 2025
The $431 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $668 · 2021: $453 · 2022: $546 · 2023: $799 · 2024: $569 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $692.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $591.95 | 2020-2023 | Lokelma |
| Dexcom, INC. | $460.49 | 2020-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $290.91 | 2019-2024 | |
| Amgen INC. | $234.88 | 2019-2025 | Tepezza, Evenity |
| Abbott Laboratories | $230.57 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.21 | 2019-2021 | |
| Insulet Corporation | $197.63 | 2019-2025 | Omnipod |
| Mannkind Corporation | $182.85 | 2020 | |
| Medtronic, INC. | $149.36 | 2022-2023 | Minimed 780g |
| Radius Health, INC. | $148.14 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $119.03 | 2022-2024 | |
| Mozarc Medical US LLC | $100.00 | 2024 | Argyle |
| Ibsa Pharma INC. | $88.26 | 2020-2025 | Tirosint, Licart, Flector |
| Pfizer INC. | $84.91 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $80.10 | 2024 | Mild Device Kit |
| Madrigal Pharmaceuticals | $76.20 | 2025 | Rezdiffra |
| Lilly USA, LLC | $57.59 | 2020-2024 | Mounjaro |
| Abbvie INC. | $44.34 | 2024-2025 | |
| Corcept Therapeutics | $41.81 | 2022-2023 | Korlym |
| Amneal Pharmaceuticals LLC | $34.77 | 2024-2025 | Unithroid |
| Sequel Med Tech, LLC | $24.18 | 2025 | Twiist |
| Bigfoot Biomedical INC | $23.74 | 2022 | |
| Tandem Diabetes Care, INC. | $22.83 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ipsen Biopharmaceuticals, INC | $21.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Bursheh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.